Educating Patients About Lifestyle Modifications for Prostate Health

American Journal of Medicine

Volumn 121, Issue 8 SUPPL.2, 2008, Pages

  Moyad, Mark A ^a   Lowe, Franklin C ^b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

Benign prostatic hyperplasia; Cardiovascular disease; Cholesterol; Diet; Exercise; Lifestyle changes

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMFEBUTAMONE; CHOLESTEROL; HYPOXIS ROOPERI EXTRACT; PLANT EXTRACT; PYGEUM AFRICANUM EXTRACT; SABAL EXTRACT; SECALE CERALE EXTRACT; SITOSTEROL; STEROID 5ALPHA REDUCTASE INHIBITOR; URTICA DIOICA EXTRACT; VARENICLINE;

ACUPUNCTURE; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CLINICAL FEATURE; DIABETES MELLITUS; DIET; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DYSLIPIDEMIA; ETHNIC GROUP; ETHNICITY; EXERCISE; HUMAN; HYPERTENSION; LIFESTYLE; LIFESTYLE MODIFICATION; MEDICAL LITERATURE; MEDICINAL PLANT; MORBIDITY; MORTALITY; NICOTINE REPLACEMENT THERAPY; OBESITY; PATIENT EDUCATION; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE; PROSTATE HYPERTROPHY; RACE DIFFERENCE; RISK ASSESSMENT; SKIN PROTECTION; SMOKING CESSATION; TOBACCO DEPENDENCE;

EXERCISE; HEALTH BEHAVIOR; HUMANS; LIFE STYLE; MALE; PATIENT EDUCATION AS TOPIC; PHYSICAL EXAMINATION; PHYSICIAN'S ROLE; PROSTATIC HYPERPLASIA; RISK ASSESSMENT;

EID: 48149103061     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2008.05.025     Document Type: Article

References (83)

1. Sarma A.V., Wei J.T., Jacobson D.J., et al. Comparison of lower urinary tract symptom severity and associated bother between community-dwelling black and white men: the Olmsted County Study of Urinary Symptoms and Health Status and the Flint Men's Health Study. Urology 61 (2003) 1086-1091
2. Arrighi H.M., Metter E.J., Guess H.A., and Fozzard J.L. Natural history of benign prostatic hyperplasia and risk of prostatectomy: the Baltimore Longitudinal Aging Study. Urology 38 suppl 1 (1991) 4-8
3. Berry S.J., Coffey D.S., Walsh P.C., and Ewing L.L. The development of human benign prostatic hyperplasia with age. J Urol 132 (1984) 474-479
4. Kupelian V., Wei J.T., O'Leary M.P., et al., BACH Survey Investigators. Prevalence of lower urinary tract symptoms and effect on quality of life in a racially and ethnically diverse random sample: the Boston Area Community Health (BACH) Survey. Arch Intern Med 166 (2006) 2381-2387
5. Parsons J.K., Carter H.B., Partin A.W., et al. Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab 91 (2006) 2562-2568
6. Michel M.C., Heemann U., Schumacher H., Menlburger L., and Goepel M. Association of hypertension with symptoms of benign prostatic hyperplasia. J Urol 172 (2004) 1390-1393
7. 1-blockers for benign prostatic hyperplasia?. A nested case-control study. Pharmacoepidemiol Drug Saf 11 (2002) 55-61
8. Morton M.S., Turkes A., Denis L., and Griffiths K. Can dietary factors influence prostatic disease?. BJU Int 84 (1999) 549-554
9. Moyad M.A. Lifestyle changes to prevent BPH: Heart healthy = prostate healthy. Urol Nurs 23 (2003) 439-441
10. Gibbons E.P., Colen J., Nelson J.B., and Benoit R.M. Correlation between risk factors for vascular disease and the American Urological Association Symptom Score. BJU Int 99 (2007) 97-100
11. Parsons J.K. Modifiable risk factors for benign prostatic hyperplasia and lower urinary tract symptoms: new approaches to old problems. J Urol 178 (2007) 395-401
12. Lee S., Min H.G., Choi S.H., et al. Central obesity as a risk factor for prostatic hyperplasia. Obesity (Silver Spring) 14 (2006) 172-179
13. Dahle S.E., Chokkalingam A.P., Gao Y.T., Deng J., Stanczyk F.Z., and Hsing A.W. Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J Urol 168 (2002) 599-604
14. Platz E.A., Kawachi I., Rimm E.B., et al. Physical activity and benign prostatic hyperplasia. Arch Intern Med 158 (1998) 2349-2356
15. Witt D.K. Health disparities in African American males. Prim Care 33 (2006) 35-43
16. Diaz Jr. V.A. Hispanic male health disparities. Prim Care 33 (2006) 45-60
17. Jimbo M. Organizing preventive health care in men. Prim Care 33 (2006) 237-246
18. US Preventive Services Task Force. Guide to Clinical Preventive Services. 3rd edition. http://www.ahrq.gov/clinic/cps3dix.htm Accessed March 1, 2007
19. Moyad M.A. Dr. Moyad's A-Z List: Part 1. Seminars in Preventive and Alternative Medicine 1 (2005) 23-49
20. The Expert Panel. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2498
21. Lee E., Park M.-S., Shin C., et al. A high-risk group for prostatism: a population-based epidemiological study in Korea. Br J Urol 79 (1997) 736-741
22. Hammarsten J., and Hogstedt B. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol 39 (2001) 151-158
23. Sandfeldt L., and Hahn R.G. Cardiovascular risk factors correlate with prostate size in men with bladder outlet obstruction. Br J Urol Intl 92 (2003) 64-68
24. Berger A.P., Bartsch G., Deibl M., et al. Atherosclerosis as a risk factor for benign prostatic hyperplasia. BJU Int 98 (2006) 1038-1042
25. Michel M.C., Mehlbuger L., Schumacher H., Bressel H.U., and Goepel M. Effect of diabetes on lower urinary tract symptoms in patients with benign prostatic hyperplasia. J Urol 163 (2000) 1725-1729
26. Ozden C., Ozdal O.L., Urgancioglu G., Koyuncu H., Gokkaya S., and Memis A. The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. Eur Urol 51 (2007) 199-206
27. Meigs J.B., Mohr B., Barry M.J., Collins M.M., and McKinlay J.B. Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. J Clin Epidemiol 54 (2001) 935-944
28. Weisman K.M., Larijani G.E., Goldstein M.R., and Goldberg M.E. Relationship between benign prostatic hyperplasia and history of coronary artery disease in elderly men. Pharmacotherapy 20 (2000) 383-386
29. Grundy S.M., Cleeman J.I., Marz N.B., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 110 (2004) 227-239
30. Chobanian A.V., Bakris G.L., Black H.R., et al., Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, the National Heart, Lung, and Blood Institute, and the National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42 (2003) 1206-1252
31. Yun A.J., Bazar K.A., Lee P.Y., Gerber A., and Daniel S.M. The smoking gun: many conditions associated with tobacco exposure may be attributable to paradoxical compensatory autonomic responses to nicotine. Med Hypotheses 64 (2005) 1073-1079
32. Platz E.A., Rimm E.B., Kawachi I., et al. Alcohol consumption, cigarette smoking, and risk of benign prostatic hyperplasia. Am J Epidemiol 149 (1999) 106-115
33. Kupeli B., Soygur T., Aydos K., Ozdiler E., and Küpelis S. The role of cigarette smoking in prostatic enlargement. Br J Urol 80 (1997) 201-204
34. Centers for Disease Control and Prevention. Tobacco Use Among Adults-United States, 2005. [serial online]. MMWR Morbid Mortal Wkly Rep 55 (2006) 1145-1148. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5644a2.htm http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5644a2.htm Accessed March 1, 2008
35. Centers for Disease Control and Prevention. Smoking & tobacco use: cessation [fact sheet]. Updated March 2007. http://www.cdc.gov/tobacco/data_statistics/Factsheets/cessation2.htm Updated April 2008. Accessed March 1, 2008
36. FDA approves novel medication for smoking cessation [press release]. FDA News [FDA Web site]. Rockville, MD: US Food and Drug Administration; May 11, 2006. Document no. P06-67. http://www.fda.gov/bbs/topics/NEWS/2006/NEW01370.html Accessed March 1, 2007
37. Wu P., Wilson K., Dimoulas P., and Mills E.J. Effectiveness of smoking cessation therapies: a systematic review and meta-analysis. BMC Public Health 6 (2006) 300
38. Eldrup E., Lindholm J., and Winkel P. Plasma sex hormones and ischemic heart disease. Clin Biochem 20 (1987) 105-114
39. Troisi R.J., Weiss S.T., and Parker D.R. Relation of obesity and diet to sympathetic nervous system activity. Hypertension 17 (1991) 669-677
40. Hammarsten J., and Hogstedt B. Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia. Blood Press 8 (1999) 29-36
41. Haslam D., Sattar N., and Lean M. Obesity-time to wake up. BMJ 333 (2006) 640-642
42. Moyad M.A. Current methods used for defining, measuring, and treating obesity. Semin Urol Oncol 19 (2001) 247-256
43. Zhu S., Heymsfield S.B., Toyoshima H., Wang Z., Pietrobelli A., and Heshka S. Race-ethnicity-specific waist circumference cutoffs for identifying cardiovascular disease risk factors. Am J Clin Nutr 81 (2005) 409-415
44. Moyad M.A. Promoting Wellness for Prostate Cancer Patients (2006), JW Edwards Publishing, Ann Arbor, MI
45. Moyad M.A. The ABCs of Nutrition and Supplements for Prostate Cancer (2003), JW Edwards Publishing, Ann Arbor, MI
46. Trojan T.H., Mody K., and Chain P. Exercise and colon cancer: primary and secondary prevention. Curr Sports Med Rep 6 (2007) 120-124
47. Kiningham R.B. Physical activity and the primary prevention of cancer. Prim Care 25 (1998) 515-536
48. Haskell W.L., Lee I.M., Pate R.R., et al. Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association. Circulation 116 (2007) 1081-1093
49. Lee Y., and Park K. Does physical activity moderate the association between depressive symptoms and disability in older adults?. Int J Geriatr Psychiatry 23 (2008) 249-256
50. Church T.S., LaMonte M.J., Barlow C.E., and Blair S.N. Cardiorespiratory fitness and body mass index as predictors of cardiovascular disease mortality among men with diabetes. Arch Intern Med 165 (2005) 2114-2120
51. Keen R. Osteoporosis: strategies for prevention and management. Best Pract Res Clin Rheumatol 21 (2007) 109-122
52. Wei M., Gibbons L.W., Kampert J.B., Nichaman M.Z., and Blair S.N. Low cardiorespiratory fitness and physical inactivity as predictors of mortality in men with type 2 diabetes. Ann Intern Med 132 (2000) 605-611
53. Cheng J.Y., Ng E.M., Ko J.S., and Chen R.Y. Physical activity and erectile dysfunction: meta-analysis of population-based studies. Int J Impot Res 19 (2007) 245-252
54. Giovannucci E., Rimm E.B., Chute C.G., et al. Obesity and benign prostatic hyperplasia. Am J Epidemiol 140 (1994) 989-1002
55. Gann P.H., Hennekens C.H., Longcope C., Verhoek-Oftedahl W., Grodstein F., and Stampfer M.J. A prospective study of plasma hormone levels, nonhormonal factors, and development of benign prostatic hyperplasia. Prostate 26 (1995) 40-49
56. Suzuki S., Platz E.A., Kawachi I., Willett W.C., and Giovannucci E. Intakes of energy and macronutrients and the risk of benign prostatic hyperplasia. Am J Clin Nutr 75 (2002) 689-697
57. Fontana L., and Klein S. Aging, adiposity, and calorie restriction. JAMA 297 (2007) 986-994
58. Heilbronn L.K., de Jonge L., Frisard M.I., et al., Pennington CALERIE Team. Effect of 6-month calorie restriction on biomarkers of longevity, metabolic adaptation, and oxidative stress in overweight individuals: a randomized controlled trial. JAMA 295 (2006) 1539-1548
59. Kristal A.R., Chi C., Tangen C.M., Goodman P.J., Etzioni R., and Thompson I.M. Associations of demographic and lifestyle characteristics with prostate-specific antigen (PSA) concentration and rate of PSA increase. Cancer 106 (2006) 320-328
60. Joseph M., Harlow S., Wei J., et al. Risk factors for lower urinary tract symptoms in a population-based sample of African-American men. Am J Epidemiol 157 (2003) 906-914
61. Bravi F., Bosetti C., Dal Maso L., et al. Macronutrients, fatty acids, cholesterol, and risk of benign prostatic hyperplasia. Urology 67 (2006) 1205-1211
62. Bravi F., Bosetti C., Dal Maso L., et al. Food groups and risk of benign prostatic hyperplasia. Urology 67 (2006) 73-79
63. Yang Y.J., Lee S.H., Hong S.J., and Chung B.C. Comparison of fatty acid profiles in the serum of patients with prostate cancer and benign prostatic hyperplasia. Clin Biochem 32 (1999) 405-409
64. Rohrmann S., Giovannucci E., Willett W.C., and Platz E.A. Fruit and vegetable consumption, intake of micronutrients, and benign prostatic hyperplasia in US men. Am J Clin Nutr 85 (2007) 523-529
65. Demark-Wahnefried W., Robertson C.N., Walther P.J., Polascik T.J., Paulson D.F., and Vollmer R.T. Pilot study to explore effects of low-fat, flaxseed-supplemented diet on proliferation of benign prostatic epithelium and prostate-specific antigen. Urology 63 (2004) 900-904
66. Tariq N., Jenkins D.J.A., Vidgen E., et al. Effect of soluble fiber diets on serum prostate specific antigen in men. J Urol 163 (2000) 114-118
67. Bent S., Kane C., Shinohara K., et al. Saw palmetto for benign prostatic hyperplasia (BPH). N Engl J Med 354 (2006) 557-566
68. Ernst E. The risk-benefit profile of commonly used herbal therapies: ginkgo, St. John's wort, ginseng, echinacea, saw palmetto, and kava. Ann Intern Med 136 (2002) 42-53
69. Martinez M., Maislos S., and Rayford W. How to engage the Latino or African American patient with benign prostatic hyperplasia: crossing socioeconomic and cultural barriers. Am J Med 121 (2008) S11-S17 [suppl]
70. Weinrich S., Priest J.H., Moyad M.A., and Weinrich M.C. Intake of selected nutritional supplements by African-American men. Urology 64 (2004) 1094-1097
71. AUA Practice Guidelines Committee. AUA Guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations. J Urol 170 (2003) 530-547
72. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta-carotene, and zinc for age-related macular degeneration and vision loss: AREDS Report Number 8. Arch Ophthalmol 119 (2001) 1417-1436
73. Johnson A.R., Munoz A., Gottlieb J.L., and Jarrard D.F. High dose zinc increases hospital admissions due to genitourinary complications. J Urol 177 (2007) 639-643
74. Lagiou P., Wuu J., Trichopoulou A., Hsien C.C., Adami H.O., and Trichopoulas D. Diet and benign prostatic hyperplasia: a study in Greece. Urology 54 (1999) 284-290
75. Leitzmann M.F., Stampfer M.J., Wu K., Colditz G.A., Willett W.C., and Giovannucci E.L. Zinc supplement use and risk of prostate cancer. J Natl Cancer Inst 95 (2003) 1004-1007
76. Moyad M.A. Zinc for prostate disease and other conditions: a little evidence, a lot of hype, and a significant potential problem. Urol Nurs 24 (2004) 49-52
77. Chandra R.K. Excessive intake of zinc impairs immune responses. JAMA 252 (1984) 1443-1446
78. Food and Nutrition Board, National Academy of Sciences. Dietary Reference Intakes For Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, And Zinc (2001), National Academy Press, Washington, DC 177-204 351-398
79. Huff J.D., Keung Y.K., Thakuri M., et al. Copper deficiency causes reversible myelodysplasia. Am J Hematol 82 (2007) 625-630
80. Kumar N. Copper deficiency myelopathy (human swayback). Mayo Clin Proc 81 (2006) 1371-1384
81. Willis M.S., Monaghan S.A., Miller M.L., et al. Zinc-induced copper deficiency: a report of three cases initially recognized on bone marrow examination. Am J Clin Pathol 123 (2005) 125-131
82. Fagelman E., and Lowe F.C. Herbal medications in the treatment of benign prostatic hyperplasia (BPH). Urol Clin North Am 29 (2002) 23-29
83. Corbie-Smith G., Thomas S.B., and St. George D.M. Distrust, race, and research. Arch Intern Med 162 (2002) 2458-2463